Novavax Inc. (NVAX) Plunged To A New Low After Phase 3 Studies Failed

Novavax Inc. (NVAX) announced after the close Thursday that a pair of Phase 3 trials of its RSV F Vaccine in older adults did not meet the pre-specified primary or the secondary efficacy objectives and did not demonstrate vaccine efficacy.

from RTT - Before the Bell http://ift.tt/2cXTZUd
via IFTTT